. Author manuscript; available in PMC: 2016 Mar 15.

Published in final edited form as: Cancer. 2014 Nov 19;121(6):876–882. doi: 10.1002/cncr.29145

Table 3. Staging at the Time of HMA Failure and Outcome After HMA Failure^a.

			TFS			OS

				%			%

Scoring System		No. (%)	Median, Months	1-Year	3-Year	Median, Months	1-Year	3-Year
IPSS	Low	69 (24)	34	82	58	33	90	62
	Int-1	155 (53)	21	65	37	26	77	38
	Int-2	43 (15)	5	17	8	7	37	10
	High	23 (8)	2	15	0	8	39	0
IPSS-R	Very low	31 (11)	33	76	58	51	82	62
	Low	87 (30)	31	76	42	31	79	47
	Int	84 (29)	21	55	36	22	68	38
	High	58 (20)	5	23	10	9	38	10
MDGSS	Very high	29 (10)	4	22	10	7	36	10
	Low	51 (18)	30	79	45	36	77	60
	Int-1	104 (36)	29	75	40	29	75	51
	Int-2	85 (29)	10	58	18	12	60	21
	Poor	50 (17)	5	30	10	8	32	10

Abbreviations: HMA, hypomethylating agent; Int, intermediate; IPSS, International Prognostic Scoring System; IPSS-R, revised International Prognostic Scoring System; MDGSS, The University of Texas MD Anderson Global Scoring System; OS, overall survival; TFS, transformation-free survival.

This table summarizes TFS and OS (median and at 1-year and 3-year) after HMA failure according to the IPSS, IPSS-R, and MGGSS at the time of HMA failure.

Table 3. Staging at the Time of HMA Failure and Outcome After HMA Failurea.

Table 3. Staging at the Time of HMA Failure and Outcome After HMA Failure^a.